The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
The EMBO Journal · 01.03.2023 · 42 (5)
DOI: 10.15252/embj.2022111556 ↗Kurz gefasst
Fachartikel in der Zeitschrift The EMBO Journal, online erschienen am 02.02.2023. Verfasst von Alan Kennedy und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCL Institute of Immunity and Transplantation, London, UK. Hauptthemen laut MEDLINE: Immune Checkpoint Proteins, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Versus Arthritis, Medical Research Council.
Abstract (Originalsprache)
CTLA‐4 and PD‐1 are key immune checkpoint receptors that are targeted in the treatment of cancer. A recently identified physical interaction between the respective ligands, CD80 and PD‐L1, has been shown to block PD‐L1/PD‐1 binding and to prevent PD‐L1 inhibitory functions. Since CTLA‐4 is known to capture and degrade its ligands via transendocytosis, we investigated the interplay between CD80 transendocytosis and CD80/PD‐L1 interaction. We find that transendocytosis of CD80 results in a time‐dependent recovery of PD‐L1 availability that correlates with CD80 removal. Moreover, CD80 transendocytosis is highly specific in that only CD80 is internalised, while its heterodimeric PD‐L1 partner remains on the plasma membrane of the antigen‐presenting cell (APC). CTLA‐4 interactions with CD80 do not appear to be inhibited by PD‐L1, but efficient removal of CD80 requires an intact CTLA‐4 cytoplasmic domain, distinguishing this process from more general trogocytosis and simple CTLA‐4 binding to CD80/PD‐L1 complexes. These data are consistent with CTLA‐4 acting as modulator of PD‐L1:PD‐1 interactions via control of CD80.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL Institute of Immunity and Transplantation, London, UK.
- Early Oncology R&D, AstraZeneca, UK.
ORCID-Profile: Alan Kennedy, Maximillian A Robinson, Claudia Hinze, David M Sansom
Förderung
- Wellcome Trust
- Versus Arthritis
- Medical Research Council
- AstraZeneca
Zitieren
APA
Kennedy, A., Robinson, M. A., Hinze, C., Waters, E., Williams, C., Halliday, N., Dovedi, S., & Sansom, D. M. (2023). The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80. The EMBO Journal, 42(5). https://doi.org/10.15252/embj.2022111556
Vancouver
Kennedy A, Robinson MA, Hinze C, Waters E, Williams C, Halliday N, et al. The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80. The EMBO Journal. 2023;42(5). doi:10.15252/embj.2022111556
BibTeX
@article{Kennedy2023,
author = {Kennedy, Alan and Robinson, Maximillian A and Hinze, Claudia and Waters, Erin and Williams, Cayman and Halliday, Neil and Dovedi, Simon and Sansom, David M},
title = {The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80},
journal = {The EMBO Journal},
year = {2023},
volume = {42},
number = {5},
doi = {10.15252/embj.2022111556}
}
EUVIMED